2.17
price down icon5.24%   -0.12
 
loading
Schlusskurs vom Vortag:
$2.29
Offen:
$2.4
24-Stunden-Volumen:
65,813
Relative Volume:
1.19
Marktkapitalisierung:
$101.29M
Einnahmen:
$134.00K
Nettoeinkommen (Verlust:
$-9.93M
KGV:
-6.3824
EPS:
-0.34
Netto-Cashflow:
$-6.72M
1W Leistung:
-2.69%
1M Leistung:
+35.62%
6M Leistung:
+24.71%
1J Leistung:
-9.21%
1-Tages-Spanne:
Value
$2.165
$2.41
1-Wochen-Bereich:
Value
$2.08
$2.44
52-Wochen-Spanne:
Value
$1.41
$2.79

Entera Bio Ltd Stock (ENTX) Company Profile

Name
Firmenname
Entera Bio Ltd
Name
Telefon
972-2-532-7151
Name
Adresse
KIRYAT HADASSAH, MINRAV BUILDING, JERUSALEM
Name
Mitarbeiter
20
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-12
Name
Neueste SEC-Einreichungen
Name
ENTX's Discussions on Twitter

Vergleichen Sie ENTX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ENTX
Entera Bio Ltd
2.17 101.29M 134.00K -9.93M -6.72M -0.34
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.03 129.44B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.52 61.42B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
615.11 38.44B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
269.81 33.29B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
241.75 26.95B 3.81B -644.79M -669.77M -6.24

Entera Bio Ltd Stock (ENTX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-03-22 Eingeleitet Aegis Capital Buy

Entera Bio Ltd Aktie (ENTX) Neueste Nachrichten

pulisher
May 02, 2025

Entera Bio (ENTX) to Release Earnings on Friday - Defense World

May 02, 2025
pulisher
Apr 24, 2025

Entera Bio (NASDAQ:ENTX) Trading Up 5.6% – Time to Buy? - Defense World

Apr 24, 2025
pulisher
Apr 15, 2025

Entera Bio reports positive phase 2 results for osteoporosis treatment By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Entera Bio reports positive phase 2 results for osteoporosis treatment - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Game-Changing Oral Osteoporosis Treatment Matches Injectable Efficacy in Clinical Trial - Stock Titan

Apr 15, 2025
pulisher
Apr 15, 2025

Entera Bio's EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with OsteoporosisHighlighted as Oral Presentation at WCO-IOF ESCEO - The Manila Times

Apr 15, 2025
pulisher
Apr 02, 2025

Entera Bio Ltd reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 02, 2025
pulisher
Apr 01, 2025

Entera Bio (NASDAQ:ENTX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat

Apr 01, 2025
pulisher
Mar 29, 2025

Entera Bio Reports Transformative Year in 2024 - TipRanks

Mar 29, 2025
pulisher
Mar 28, 2025

Entera Bio Ltd. (ENTX) reports earnings - Quartz

Mar 28, 2025
pulisher
Mar 28, 2025

Entera Bio Announces 2024 Financial Results and Updates - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Entera Bio's Breakthrough: Oral Peptide Programs Show Promise as 2024 Results Reveal $21M War Chest - Stock Titan

Mar 28, 2025
pulisher
Mar 28, 2025

Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire

Mar 28, 2025
pulisher
Mar 21, 2025

Entera Bio Ltd expected to post a loss of 8 cents a shareEarnings Preview - TradingView

Mar 21, 2025
pulisher
Mar 19, 2025

Entera Bio’s (ENTX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

OPKO And Entera Bio Team Up For Game-Changing Obesity Pill - Finimize

Mar 18, 2025
pulisher
Mar 18, 2025

Opko Health, Entera Bio sign agreement for oral GLP-1/glucagon dual agonist peptide - BioWorld MedTech

Mar 18, 2025
pulisher
Mar 18, 2025

OPKO and Entera team up on oral obesity candidate - The Pharma Letter

Mar 18, 2025
pulisher
Mar 18, 2025

OPKO and Entera Bio partner on oral obesity treatment By Investing.com - Investing.com Australia

Mar 18, 2025
pulisher
Mar 17, 2025

OPKO and Entera partner to develop obesity pill -March 17, 2025 at 08:54 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Entera Bio Collaborates with OPKO for Oral GLP-1/Glucagon - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

OPKO, Entera to Co-Develop Oral GLP-1/Glucagon Therapy for Obesity -March 17, 2025 at 08:38 am EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

OPKO and Entera Bio partner on oral obesity treatment - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

OPKO Health and Entera Bio Enter into Collaboration - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

OPKO Health (OPK) and Entera Bio (ENTX) Enter into Collaboration Agreement - StreetInsider

Mar 17, 2025
pulisher
Mar 17, 2025

Revolutionary Oral GLP-1 Obesity Treatment: OPKO and Entera Join Forces to Challenge Injectable Market - StockTitan

Mar 17, 2025
pulisher
Mar 17, 2025

Revolutionary Oral GLP-1 Obesity Treatment: OPKO and Entera Bio Join Forces for Game-Changing Pill - Stock Titan

Mar 17, 2025
pulisher
Mar 07, 2025

Entera Bio (ENTX) Expected to Announce Quarterly Earnings on Friday - Defense World

Mar 07, 2025
pulisher
Feb 28, 2025

Entera Bio Ltd. to Host Earnings Call - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 24, 2025

Entera Bio to Participate in Upcoming Events - GlobeNewswire

Feb 24, 2025
pulisher
Feb 24, 2025

Can Entera Bio's Upcoming Scientific Data Reshape Oral Peptide Therapy? Major Conference Schedule Revealed - Stock Titan

Feb 24, 2025
pulisher
Feb 19, 2025

EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskel - The Manila Times

Feb 19, 2025
pulisher
Feb 19, 2025

Could This Oral Osteoporosis Treatment Replace Daily Injections? Phase 2 Data Reveals Promising Results - StockTitan

Feb 19, 2025
pulisher
Feb 17, 2025

Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 31.6% in January - MarketBeat

Feb 17, 2025
pulisher
Feb 07, 2025

US Penny Stocks: 3 Picks With Market Caps Over $60M - Yahoo Finance

Feb 07, 2025
pulisher
Feb 06, 2025

Is Entera Bio (NASDAQ:ENTX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Feb 06, 2025
pulisher
Feb 04, 2025

Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Increase in Short Interest - MarketBeat

Feb 04, 2025
pulisher
Feb 03, 2025

145,843 Shares in Entera Bio Ltd. (NASDAQ:ENTX) Acquired by Perigon Wealth Management LLC - MarketBeat

Feb 03, 2025
pulisher
Feb 03, 2025

Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 23.1% in January - MarketBeat

Feb 03, 2025
pulisher
Jan 27, 2025

Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire

Jan 27, 2025
pulisher
Jan 27, 2025

Entera Bio CEO to Present Business Updates at Oppenheimer Healthcare Conference - StockTitan

Jan 27, 2025
pulisher
Jan 18, 2025

Entera Bio Ltd. (NASDAQ:ENTX) Sees Significant Decrease in Short Interest - Defense World

Jan 18, 2025

Finanzdaten der Entera Bio Ltd-Aktie (ENTX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.42
price down icon 5.24%
$67.87
price down icon 6.49%
$32.11
price down icon 2.70%
$24.20
price down icon 13.63%
$94.74
price down icon 6.29%
biotechnology ONC
$241.75
price down icon 4.88%
Kapitalisierung:     |  Volumen (24h):